Arcutis Biotherapeutics, Inc.: dividend

ARQTNASDAQHealthcare · Pharmaceutical Preparations

Price

$27.45

November 16, 2026Market cap $3.4B

What Ploutos Investor adds for Arcutis Biotherapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
  • Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.

Arcutis Biotherapeutics pays no dividend

It paid no dividend in any of the fiscal years we hold, nor over the last 12 months. Nor does it buy back shares: its share count rose 4.6% in a year.

All dividend stocks

The full analysis

What do Arcutis Biotherapeutics's filings show?

The dividend is one part of Arcutis Biotherapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ARQT's dividend

Didn't find what you were looking for?

Ask us
Does ARQT pay a dividend?

It paid no dividend in any of the fiscal years we hold, nor over the last 12 months. Nor does it buy back shares: its share count rose 4.6% in a year.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.